Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 187004 Tablet vs Solution and Food Effect
NCT02161432Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 187004 in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point and Maximum measured concentration. Started Jun 2014; status: completed.
02
Drugs
BI 187004
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02161432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161432.